DCBO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Docebo Inc (DCBO) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company's financial performance shows impressive YoY growth in revenue, net income, and EPS, the technical indicators suggest a bearish trend, and the stock is likely to decline further in the short term. Additionally, analysts have lowered price targets, and there are no significant positive catalysts or recent news to support immediate upside potential. It is better to wait for clearer signs of recovery or a more favorable entry point.
The technical indicators show a bearish trend. The MACD is negatively expanding, RSI is neutral at 29.159, and the moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 19.029 and the next support at 17.397. Short-term stock trend analysis indicates a 70% chance of further decline (-1.37% in the next day, -2.26% in the next week, -9.58% in the next month).
Hedge funds have significantly increased their buying activity by 1100% over the last quarter. The company's financials for Q4 2025 show strong YoY growth in revenue (+10.51%), net income (+125.47%), and EPS (+156.41%). Analysts acknowledge underlying business strength despite headwinds.
Bearish technical indicators and short-term stock trend predictions suggest further price declines. Analysts have lowered price targets and expect shares to remain rangebound in the near term. Gross margin decreased by -1.62% YoY. There are no recent news catalysts or congress trading data to support the stock.
In Q4 2025, Docebo reported revenue growth of 10.51% YoY to $63.037M, net income growth of 125.47% YoY to $26.853M, and EPS growth of 156.41% YoY to $1. However, gross margin declined by -1.62% YoY to 78.52%.
Analysts have lowered their price targets: Stifel to $28 (from $34), Morgan Stanley to $26 (from $28), and Scotiabank to $25 (from $32). While analysts recognize strong gross bookings and underlying business health, they expect shares to remain rangebound in the near term due to headwinds like the AWS contract roll-off and Dayforce churn.
